Entyvio® (vedolizumab) – New formulation approval
September 27, 2023 - Takeda announced the FDA approval of a subcutaneous (SC) formulation of Entyvio (vedolizumab), for the maintenance treatment of moderately to severely active ulcerative colitis (UC).
Download PDF
